Literature DB >> 15016870

Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IX.

Jort Vellinga1, Martijn J W E Rabelink, Steve J Cramer, Diana J M van den Wollenberg, Hans Van der Meulen, Keith N Leppard, Frits J Fallaux, Rob C Hoeben.   

Abstract

The efficiency and specificity of gene transfer with human adenovirus (hAd)-derived gene transfer vectors would be improved if the native viral tropism could be modified. Here, we demonstrate that the minor capsid protein IX (pIX), which is present in 240 copies in the Ad capsid, can be exploited as an anchor for heterologous polypeptides. Protein IX-deleted hAd5 vectors were propagated in hAd5 helper cells expressing pIX variants, with heterologous carboxyl-terminal extensions of up to 113 amino acids in length. The extensions evaluated consist of alpha-helical spacers up to 75 A in length and to which peptide ligands were fused. The pIX variants were efficiently incorporated into the capsids of Ad particles. On intact particles, the MYC-tagged-pIX molecules were readily accessible to anti-MYC antibodies, as demonstrated by electron microscopic analyses of immunogold-labeled virus particles. The labeling efficiency improved with increasing spacer length, suggesting that the spacers lift and expose the ligand at the capsid surface. Furthermore, we found that the addition of an integrin-binding RGD motif to the pIX markedly stimulated the transduction of coxsackievirus group B and hAd receptor-deficient endothelioma cells, demonstrating the utility of pIX modification in gene transfer. Our data demonstrate that the minor capsid protein IX can be used as an anchor for the addition of polypeptide ligands to Ad particles.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016870      PMCID: PMC371045          DOI: 10.1128/jvi.78.7.3470-3479.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

Review 1.  Targeted adenoviral vectors.

Authors:  Brian G Barnett; C Jefferson Crews; Joanne T Douglas
Journal:  Biochim Biophys Acta       Date:  2002-05-03

2.  Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein.

Authors:  Natalya Belousova; Valentina Krendelchtchikova; David T Curiel; Victor Krasnykh
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

3.  Genetic retargeting of adenovirus vectors: functionality of targeting ligands and their influence on virus viability.

Authors:  Maria K Magnusson; Saw See Hong; Petra Henning; Pierre Boulanger; Leif Lindholm
Journal:  J Gene Med       Date:  2002 Jul-Aug       Impact factor: 4.565

4.  Two-stage selection of sequences from a random phage display library delineates both core residues and permitted structural range within an epitope.

Authors:  R M Miceli; M E DeGraaf; H D Fischer
Journal:  J Immunol Methods       Date:  1994-01-03       Impact factor: 2.303

5.  Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo.

Authors:  Sabine Zitzmann; Volker Ehemann; Manfred Schwab
Journal:  Cancer Res       Date:  2002-09-15       Impact factor: 12.701

6.  Constitutive episomal expression of polypeptide IX (pIX) in a 293-based cell line complements the deficiency of pIX mutant adenovirus type 5.

Authors:  C Caravokyri; K N Leppard
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX.

Authors:  Igor P Dmitriev; Elena A Kashentseva; David T Curiel
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting.

Authors:  Astrid J Schraa; Robbert J Kok; Agnes D Berendsen; Henk E Moorlag; Erwin J Bos; Dirk K F Meijer; Lou F M H de Leij; Grietje Molema
Journal:  J Control Release       Date:  2002-10-04       Impact factor: 9.776

9.  Genetic modification of adenovirus 5 tropism by a novel class of ligands based on a three-helix bundle scaffold derived from staphylococcal protein A.

Authors:  P Henning; M K Magnusson; E Gunneriusson; S S Hong; P Boulanger; P-A Nygren; L Lindholm
Journal:  Hum Gene Ther       Date:  2002-08-10       Impact factor: 5.695

10.  Subgroup B and F fiber chimeras eliminate normal adenovirus type 5 vector transduction in vitro and in vivo.

Authors:  John W Schoggins; Jason G D Gall; Erik Falck-Pedersen
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  28 in total

1.  Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, Δ24DoubleRGD, in an ovarian cancer model.

Authors:  Lena J Gamble; Hideyo Ugai; Minghui Wang; Anton V Borovjagin; Qiana L Matthews
Journal:  J Mol Biochem       Date:  2012-02-15

2.  Fusion of Large Polypeptides to Human Adenovirus Type 5 Capsid Protein IX Can Compromise Virion Stability and DNA Packaging Capacity.

Authors:  Kathy L Poulin; Emily R McFall; Grace Chan; Natacha B Provost; Carin Christou; Adam C Smith; Robin J Parks
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

3.  The coiled-coil domain of the adenovirus type 5 protein IX is dispensable for capsid incorporation and thermostability.

Authors:  Jort Vellinga; Diana J M van den Wollenberg; Stephanie van der Heijdt; Martijn J W E Rabelink; Rob C Hoeben
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion.

Authors:  Qiana L Matthews; Don A Sibley; Hongju Wu; Jing Li; Mariam A Stoff-Khalili; Reinhard Waehler; J Michael Mathis; David T Curiel
Journal:  Mol Imaging       Date:  2006 Oct-Dec       Impact factor: 4.488

Review 5.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

6.  Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity.

Authors:  Anja Krause; Ju H Joh; Neil R Hackett; Peter W Roelvink; Joseph T Bruder; Thomas J Wickham; Imre Kovesdi; Ronald G Crystal; Stefan Worgall
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

7.  Cryoelectron microscopy of protein IX-modified adenoviruses suggests a new position for the C terminus of protein IX.

Authors:  Michael P Marsh; Samuel K Campos; Matthew L Baker; Christopher Y Chen; Wah Chiu; Michael A Barry
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

8.  Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review).

Authors:  Lena J Gamble; Anton V Borovjagin; Qiana L Matthews
Journal:  Exp Ther Med       Date:  2010-03       Impact factor: 2.447

Review 9.  Current advances and future challenges in Adenoviral vector biology and targeting.

Authors:  Samuel K Campos; Michael A Barry
Journal:  Curr Gene Ther       Date:  2007-06       Impact factor: 4.391

10.  Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.

Authors:  Wibke Bayer; Matthias Tenbusch; Ruth Lietz; Lena Johrden; Simone Schimmer; Klaus Uberla; Ulf Dittmer; Oliver Wildner
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.